Literature DB >> 932142

Quantitative assay of sulphinpyrazone in plasma and urine by high-performance liquid chromatography.

J B Lecaillon, C Souppart.   

Abstract

A method for the quantitative determination of sulphinpyrazone in plasma and urine is described. The drug is extracted from the acidified aqueous phase with 1-chlorobutane-ethylene dichloride (4:1) and separated from its metabolites by high-performance liquid chromatography on 5-mum LiChrosorb using dichloromethane-ethanol-water-acetic acid (79.1:19:1.9:0.002) as the mobile phase. The sensitivity limit is 0,2mug/ml using a 1-ml sample. Examples of applications are given.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 932142     DOI: 10.1016/s0021-9673(00)85018-9

Source DB:  PubMed          Journal:  J Chromatogr


  5 in total

1.  Plasma levels and pharmacokinetics of sulphinpyrazone in renal impairment during chronic treatment: a case report.

Authors:  J Godbillon; J P Schoeller; S Gauron; G Gosset; J P Fillastre
Journal:  Br J Clin Pharmacol       Date:  1984-07       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics and potentially important drug interactions of sulphinpyrazone.

Authors:  A K Pedersen; P Jakobsen; J P Kampmann; J M Hansen
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

3.  Determination of sulfinpyrazone and four metabolites in plasma and urine by high pressure liquid chromatography.

Authors:  E G Lentjes; Y Tan; C A Van Ginneken
Journal:  Pharm Weekbl Sci       Date:  1985-12-13

4.  Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine.

Authors:  I D Bradbrook; V A John; P J Morrison; H J Rogers; R G Spector
Journal:  Br J Clin Pharmacol       Date:  1982-02       Impact factor: 4.335

5.  Receptor-directed inhibition of chemotactic factor-induced neutrophil hyperactivity by pyrazolon derivatives. Definition of a chemotactic peptide antagonist.

Authors:  C Dahinden; J Fehr
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.